Valuation: Synovics Pharmaceuticals, Inc.

Market Cap 1.64M 1.46M 1.36M 1.24M 2.34M 158M 2.35M 16.46M 6.4M 80.57M 6.16M 6.03M 259M P/E 2007
-0.73x
P/E 2008 -2.06x
Enterprise Value 8.13M 7.24M 6.75M 6.15M 11.59M 783M 11.66M 81.55M 31.7M 399M 30.52M 29.85M 1.28B EV / Sales 2007
1.81x
EV / Sales 2008 0.6x
Free-Float
95.75%
Yield 2007 *
-
Yield 2008 -
1 day-50.00%
6 months+9,900.00%
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 1.0E-6
0
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-.--%-.--%-.--% 3.65K
+0.02%-3.41%+36.11%+115.09% 1,019B
-1.21%-6.74%+34.08%+62.64% 617B
+1.12%+0.54%+13.62%+79.94% 464B
-3.30%-6.21%+56.45%+36.58% 356B
+0.93%-3.16%+21.65%+43.02% 333B
+0.12%-2.77%+10.70%+32.97% 267B
-0.89%-6.28%-7.00%+8.01% 244B
-0.01%-2.81%+35.28%+51.82% 218B
-0.08%-4.17%+28.34%+93.51% 179B
Average -5.26%-3.19%+22.92%+52.36% 369.72B
Weighted average by Cap. -0.04%-3.54%+28.50%+70.11%

Financials

2007 2008
Net sales 23.47M 20.91M 19.49M 17.75M 33.45M 2.26B 33.66M 235M 91.52M 1.15B 88.09M 86.18M 3.71B 25.96M 23.13M 21.57M 19.63M 37.01M 2.5B 37.23M 260M 101M 1.27B 97.45M 95.34M 4.1B
Net income -20.86M -18.59M -17.33M -15.77M -29.73M -2.01B -29.92M -209M -81.34M -1.02B -78.3M -76.6M -3.29B -4.01M -3.57M -3.33M -3.03M -5.71M -386M -5.75M -40.19M -15.62M -197M -15.04M -14.71M -633M
Net Debt 18.79M 16.75M 15.61M 14.21M 26.79M 1.81B 26.95M 189M 73.28M 923M 70.54M 69.01M 2.97B 6.49M 5.78M 5.39M 4.91M 9.25M 625M 9.31M 65.09M 25.3M 319M 24.36M 23.83M 1.02B
Logo Synovics Pharmaceuticals, Inc.
Synovics Pharmaceuticals, Inc. (Synovics) is a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of generic over the counter (OTC) pharmaceutical products and generic prescription drug products. The Company is a manufacturer, packager and distributor of private label, or store brand, OTC products to chain drug stores, wholesalers and distributors throughout the United States. The Company’s OTC product categories include analgesics, cough and cold, antihistamines, asthma relief and laxatives. The Company has two primary subsidiaries, Kirk Pharmaceuticals, LLC (Kirk), and ANDAPharm, LLC (ANDAPharm). Kirk manufactures and distributes OTC products developed by or licensed to the Company. ANDAPharm serves as the product research and RX manufacturing arm of the Company with a focus on the development of active compounds for drugs.
Employees
155
  1. Stock Market
  2. Stocks
  3. SYVC Stock